As breast cancer with a high level expression of Cdc6 were less responsive to ER inhibition, it is tempting to speculate that the modality of combining inhibitions of ER and other pathways may be more beneficial to patients with high level of Cdc6, who respond less well to ER inhibition alone. Here, ESR1 is linked to breast carcinoma.